CRABP2 affects chemotherapy resistance of ovarian cancer by regulating the expression of HIF1α
Authors:
Top Cited Papers
Open Access
- 9 January 2024
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (1) , 1-13
Abstract
Ovarian cancer is the most lethal malignancy among gynecologic cancers, and primary and secondary chemotherapy resistance is one of the important reasons for poor prognosis of ovarian cancer patients. However, the specifics of resistance to chemotherapy in ovarian cancer remain unclear. Herein, we find that the expression level of cellular retinoic acid binding protein 2 (CRABP2) is up-regulated in drug-resistant ovarian cancer tissues and cell lines, and the expression levels of CRABP2 in epithelial ovarian cancer tissues are closely related to tumor clinical stage and patients’ prognosis, suggesting that CRABP2 plays an important role in the progression of ovarian cancer and the corresponding ability of tumor to chemotherapy. With the in-depth study, we demonstrates that CRABP2 is related to the high metabolic activity in drug-resistant cells, and all-trans retinoic acid exacerbates this activity. Further molecular mechanism exploration experiments show that CRABP2 not only up-regulates the expression level of HIF1α, but also increases the localization of HIF1α in the nucleus. In drug-resistant ovarian cancer cells, knocking down HIF1α can block the resistance of CRABP2 to chemotherapy drugs in ovarian cancer cells. Taken together, our findings suggest for the first time that CRABP2 affects chemotherapy resistance of ovarian cancer by regulating the expression of HIF1α. This study provides a possible molecular mechanism for drug resistance and a possible molecular target for clinical treatment of ovarian cancer.Keywords
Funding Information
- Seed Foundation of Tianjin Medical University Cancer Institute and Hospital
This publication has 45 references indexed in Scilit:
- ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cellsInternational Journal of Oncology, 2018
- Plasma CRABP2 as a Novel Biomarker in Patients with Non-Small Cell Lung CancerJournal of Korean Medical Science, 2018
- HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolismNature Communications, 2017
- Bioenergetic Adaptations in Chemoresistant Ovarian Cancer CellsScientific Reports, 2017
- Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancerCell Death & Differentiation, 2016
- Transcript Stabilization by the RNA-Binding Protein HuR Is Regulated by Cellular Retinoic Acid-Binding Protein 2Molecular and Cellular Biology, 2014
- Duplicated crabp1 and crabp2 genes in medaka (Oryzias latipes): Gene structure, phylogenetic relationship and tissue-specific distribution of transcriptsComparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology, 2013
- Nuclear Translocation of Cellular Retinoic Acid-binding Protein II Is Regulated by Retinoic Acid-controlled SUMOylationJournal of Biological Chemistry, 2011
- Epigenetic Silencing of CRABP2 and MX1 in Head and Neck TumorsNeoplasia, 2009
- Retinoic acid pathway genes show significantly altered expression in uterine fibroids when compared with normal myometriumMolecular Human Reproduction, 2007